(0.34%) 5 109.00 points
(0.74%) 38 667 points
(0.60%) 17 756 points
(0.61%) $79.43
(0.88%) $2.05
(-0.10%) $2 307.20
(-0.54%) $26.69
(0.75%) $969.80
(-0.24%) $0.930
(-0.90%) $10.89
(-0.22%) $0.796
(0.62%) $91.69
0.00% $ 0.0428
Live Chart Being Loaded With Signals
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory...
Stats | |
---|---|
Dzisiejszy wolumen | 550.00 |
Średni wolumen | 2 503.00 |
Kapitalizacja rynkowa | 2.78M |
EPS | $-0.0133 ( 2023-10-23 ) |
Następna data zysków | ( $0 ) 2024-05-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.28 |
ATR14 | $0 (0.00%) |
RepliCel Life Sciences Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
RepliCel Life Sciences Finanse
Annual | 2022 |
Przychody: | $353 735 |
Zysk brutto: | $353 735 (100.00 %) |
EPS: | $-0.0341 |
FY | 2022 |
Przychody: | $353 735 |
Zysk brutto: | $353 735 (100.00 %) |
EPS: | $-0.0341 |
FY | 2021 |
Przychody: | $353 735 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.151 |
FY | 2020 |
Przychody: | $353 735 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.0600 |
Financial Reports:
No articles found.
RepliCel Life Sciences
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej